{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:35:23Z","timestamp":1792733723719,"version":"4.5.0"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma GmbH, Germany","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,8,7]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Data on long-term outcomes of antivascular endothelial growth factor therapy in retinopathy of prematurity (ROP) are still rare. We present 5-year post-treatment ophthalmological and paediatric outcomes of the prospective, multicentre, randomised, double-blinded, controlled pilot study CARE-ROP (Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>14 patients (28 eyes) completed the ophthalmologic and 5 patients completed the paediatric 5-year follow-up assessment. The ophthalmological assessment included best-corrected visual acuity (BCVA), orthoptic status, slit lamp examination, intraocular pressure and funduscopy. The paediatric examination followed the German Neonatal Network protocol and covered cognitive, motor and sensory development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>17 of 28 eyes exhibited at least one ocular abnormality, such as optic disc pallor or atrophy of the optic nerve head, retinal pigment epithelium (RPE) pigment changes, persistent tortuosity or macular hypoplasia. Despite this, 19 of 26 eyes demonstrated a logarithm of the Minimum Angle of Resolution (logMAR) BCVA of 0.3 or better. Mean refractive error was \u22120.9 D (\u00b13.4\u2009D) with only two eyes of one infant having high myopia of &lt; \u22125 D. The neurodevelopmental results were within the expected range for a population of preterm infants with treatment-warranting ROP but need to be interpreted with caution due to the low number of five patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The 5-year ophthalmologic and paediatric outcomes of the CARE-ROP study confirm the previous results and add important additional information on long-term safety of 0.12 and 0.20\u2009mg ranibizumab for the treatment of ROP. The ophthalmologic functional outcome regarding BCVA and refraction is promising. These exploratory long-term data, however, need to be interpreted with caution due to the low patient number both in the ophthalmologic and paediatric assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002303","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T14:18:53Z","timestamp":1756217933000},"page":"e002303","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Different ranibizumab dosages for retinopathy of prematurity: 5-year follow-up data of the randomised, controlled CARE-ROP Study"],"prefix":"10.1136","volume":"10","author":[{"given":"Andreas","family":"Stahl","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University Medicine Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-1492","authenticated-orcid":false,"given":"Marie-Christine","family":"Br\u00fcnder","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medicine Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf A","family":"Lagr\u00e8ze","sequence":"additional","affiliation":[{"name":"Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanni E","family":"Moln\u00e1r","sequence":"additional","affiliation":[{"name":"Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-6171","authenticated-orcid":false,"given":"Teresa","family":"Barth","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Eter","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of M\u00fcnster Medical Center, Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6038-5577","authenticated-orcid":false,"given":"Rainer","family":"Guthoff","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2280-925X","authenticated-orcid":false,"given":"Tim U","family":"Krohne","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"G\u00f6pel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2731-6094","authenticated-orcid":false,"given":"Johanna M","family":"Pfeil","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medicine Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"2026010721210541000_10.1.e002303.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"2026010721210541000_10.1.e002303.2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"The Lancet"},{"key":"2026010721210541000_10.1.e002303.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.10564"},{"key":"2026010721210541000_10.1.e002303.4","unstructured":"EMA . Lucentis 10 mg\/ml solution for injection SmPC. Europa.eu; 2020."},{"key":"2026010721210541000_10.1.e002303.5","unstructured":"EMA . Eylea 40 mg\/ml solution for injection in pre-filled syringe SmpC. Europa.eu; 2022."},{"key":"2026010721210541000_10.1.e002303.6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"J AAPOS"},{"key":"2026010721210541000_10.1.e002303.7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.8383","article-title":"Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity: Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE next","volume":"7","author":"Stahl","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026010721210541000_10.1.e002303.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102567","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial","volume":"71","author":"Marlow","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026010721210541000_10.1.e002303.9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"},{"key":"2026010721210541000_10.1.e002303.10","doi-asserted-by":"crossref","unstructured":"Stahl A , Br\u00fcnder M , Lagr\u00e8ze WA , et al . Ranibizumab in retinopathy of prematurity \u2013 one\u2010year follow\u2010up of ophthalmic outcomes and two\u2010year follow\u2010up of neurodevelopmental outcomes from the CARE\u2010ROP study. Acta Ophthalmol (Copenh) 2022;100. doi:10.1111\/aos.14852","DOI":"10.1111\/aos.14852"},{"key":"2026010721210541000_10.1.e002303.11","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1111\/apa.16965","article-title":"Erythrocyte transfusions are associated with retinopathy of prematurity in extremely low gestational age newborns","volume":"112","author":"Glaser","year":"2023","journal-title":"Acta Paediatr"},{"key":"2026010721210541000_10.1.e002303.12","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13010042","article-title":"Influenza Immunization in Very-Low-Birth-Weight Infants: Epidemiology and Long-Term Outcomes","volume":"13","author":"Dammann","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"2026010721210541000_10.1.e002303.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.05.031"},{"key":"2026010721210541000_10.1.e002303.14","unstructured":"Bach M . Visual acuity \u201ccheat sheet\u201d for high and low vision. 2025."},{"key":"2026010721210541000_10.1.e002303.15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.oret.2023.12.002","article-title":"Treated Cases of Retinopathy of Prematurity in Germany: 10-Year Data from the Retina.net Retinopathy of Prematurity Registry","volume":"8","author":"Pfeil","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"2026010721210541000_10.1.e002303.16","doi-asserted-by":"crossref","unstructured":"Winter K , Pfeil JM , Engmann H , et al . Comparability of input parameters in the German Retina.net ROP registry and the EU\u2010ROP registry \u2013 An exemplary comparison between 2011 and 2021. Acta Ophthalmol (Copenh) 2024;102. doi:10.1111\/aos.15753","DOI":"10.1111\/aos.15753"},{"key":"2026010721210541000_10.1.e002303.17","unstructured":"Maier RF , Hummler H , Kellner U , et al . Augen\u00e4rztliche screening-untersuchung bei fr\u00fchgeborenen awmf-leitlinien-register Nr. 024\/010. 2020."},{"key":"2026010721210541000_10.1.e002303.18","unstructured":"The royal college of ophthalmologists . Treating retinopathy of prematurity in the UK. 2022."},{"key":"2026010721210541000_10.1.e002303.19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3928\/23258160-20200228-07","article-title":"Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP","volume":"51","author":"Lepore","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2026010721210541000_10.1.e002303.20","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100130413008"},{"key":"2026010721210541000_10.1.e002303.21","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2014-306207"},{"key":"2026010721210541000_10.1.e002303.22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jaapos.2022.08.524","article-title":"Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity","volume":"26","author":"Hoppe","year":"2022","journal-title":"J AAPOS"},{"key":"2026010721210541000_10.1.e002303.23","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.1.12"},{"key":"2026010721210541000_10.1.e002303.24","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2026010721210541000_10.1.e002303.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.12.017"},{"key":"2026010721210541000_10.1.e002303.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042384","article-title":"Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis","volume":"11","author":"Kong","year":"2021","journal-title":"BMJ Open"},{"key":"2026010721210541000_10.1.e002303.27","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"2026010721210541000_10.1.e002303.28","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.82.11.1265"},{"key":"2026010721210541000_10.1.e002303.29","first-page":"11854","article-title":"Refractive status and optical components of premature babies with or without retinopathy of prematurity at 3-4 years old","volume":"8","author":"Ouyang","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"2026010721210541000_10.1.e002303.30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1055\/s-0039-1694983","article-title":"Two-Year Outcomes of Infants with Stage 2 or Higher Retinopathy of Prematurity: Results from a Large Multicenter Registry","volume":"37","author":"Tolia","year":"2020","journal-title":"Am J Perinatol"},{"key":"2026010721210541000_10.1.e002303.31","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00347-012-2618-8","article-title":"Aktuelle Therapieoptionen bei Fr\u00fchgeborenenretinopathie","volume":"109","author":"Krohne","year":"2012","journal-title":"Ophthalmologe"},{"key":"2026010721210541000_10.1.e002303.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.07.005"},{"key":"2026010721210541000_10.1.e002303.33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"2026010721210541000_10.1.e002303.34","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY","volume":"37","author":"Wu","year":"2017","journal-title":"Retina (Philadelphia, Pa)"},{"key":"2026010721210541000_10.1.e002303.35","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2023-323915"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:22:05Z","timestamp":1767849725000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,26]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjophth-2025-002303"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002303","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}